SBC Medical Group Holdings Incorporated, together with its subsidiaries, provides management services to cosmetic treatment centers in Japan, Vietnam, the United States, and Singapore.
FAIL · Does not pass the screen
3.08 USD
At the last full screen 2025-12-31
Screened 2025-12-31 · the tape above runs as of 22:12 UTC · 11 Sep · two dates, stated on purpose · verdict and workings shown in full · never trimmed
The Label · The Season, Not the Day
This name holds its markup label.
SBC Medical Group Holdings Inc holds its Markup at $3.08. Consolidating, no directional conviction, held for 12 days.
As held on the ledger · 2025-12-31
Phase
Markup
Quantitative state
Consolidating, no directional conviction, held for 12 days
Price at the screen
$3.08
Valuation
7.70 trailing · 6.35 forward price to earnings
Values screen
FAIL· score 70.0
Beta
0.59
The Workings
Five Screens, Shown in Full
Does not pass. Accounts receivable
Test
Figure
Limit
What it means
Status
Business activity
Permissible
Core business clean
Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending.
Pass
Debt load
13.57%
Below 33%
Interest-bearing debt is just 13.6% of its assets, well under the one-third ceiling: it does not run on borrowed money.
Pass
Interest-bearing cash
0.08%
Below 33%
Cash held in interest-bearing accounts and securities is 0.1% of assets, under the one-third limit.
Pass
Receivables
50.91%
Below 49%
Money owed to the company is 50.9% of assets, above the 49% limit.
Fail
Revenue purity
0.11%
Below 5%
Only 0.1% of revenue comes from non-compliant sources, under the 5% line.
Pass
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
Fair value range in USD, drawn from the 2025-12-31 screen. The gold marker is the market price at the same screen. A 100.0% margin of safety to the base estimate.
Third-party analyst targets: 4 covering, consensus Strong Buy. The average target sits +176% from the screen price.
Reading the gap · Both our model and the analysts see meaningful upside from here.
Price History & Projections
Where it has been, where the models see it going. History from market close data; projection points are our fair-value estimates and third-party analyst targets, dated to the 2025-12-31 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The risks · The things to watch: it's a small-cap, so the share price can swing harder than the market.
Plain-English interpretation of our own screen data. Analysis, not advice.
The Dated Journal · Newest First, Never Edited
Every Entry, As Written
2026-09-12Markup · changed$3.08+0.0%Entry 5
The framework has shifted from markdown to markup since the last review. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it C. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 37%. Our forward projection puts the odds of a 10% gain over the next month near 21%. The street (4 analysts) rates it none, with a mean price target of $8.
2026-08-12Markdown$3.08+7.3%Entry 4
The framework reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved up 7.3% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it C. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 37%. Our forward projection puts the odds of a 10% gain over the next month near 21%. The street (4 analysts) rates it none, with a mean price target of $8.
2026-07-18Markdown$2.87+0.0%Entry 3
The framework reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it C. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 37%. Our forward projection puts the odds of a 10% gain over the next month near 21%. The street (4 analysts) rates it none, with a mean price target of $8.
2026-07-03Markdown$2.87+0.0%Entry 2
The framework reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows negative risk-adjusted returns.
2026-07-02Markdown$2.87Entry 1
The framework reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows negative risk-adjusted returns.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.